Human Tetanus Immunoglobulin

ইঙ্গিত

Tetagam-P is indicated for the prophylaxis of tetanus following injury in patients whose immunization is incomplete or uncertain, as well as for the therapeutic treatment of tetanus. Tetanus immunoglobulin should always be given together with an active tetanus vaccination, unless contraindications exist or adequate vaccination has already been confirmed.

⚠️ কোনো ওষুধ গ্রহণের আগে সর্বদা নিবন্ধিত চিকিৎসকের পরামর্শ নিন।

ফার্মাকোলজি

Human tetanus immunoglobulin works by neutralizing tetanus toxin before it can harm the body's tissues. It binds directly to the toxin produced by *Clostridium tetani*, blocking its normal interaction with human tissue. In doing so, it stops the toxin from reaching the nervous system, where it would otherwise trigger painful muscle spasms and disrupt the body's automatic (autonomic) functions. The bacteria themselves are cleared either by antibiotic treatment or by the host's own immune defenses, while the toxin-antibody complexes formed by the immune globulin are thought to be broken down by the body's phagocytic immune cells.

Pregnancy & Breastfeeding

Safety in human pregnancy has not been confirmed through controlled clinical trials. That said, long-standing clinical experience with immunoglobulins as a class suggests they are not expected to harm the course of pregnancy or affect the developing baby, whether before or after birth.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

ডোজ নির্দেশিকা

⚠️ শুধুমাত্র সরকারি উৎস থেকে নির্দেশিকা পরিসীমা। ব্যক্তিগতকৃত ডোজের জন্য আপনার ডাক্তারের পরামর্শ নিন।

Adults: Post-exposure prophylaxis of tetanus: For adults and children, a single dose of 250 IU should be given. The dose may be increased to 500 IU in the following cases: infected wounds where surgically appropriate treatment cannot be achieved within 24 hours; deep or contaminated wounds with tissue damage and reduced oxygen supply, as well as foreign body injury (e.g., bites, stings or shots); burns; frostbite; tissue necrosis; septicaemic abortion; and adults weighing more than the average. In case of extensive burns, it is advisable to administer a second injection of 250 IU human tetanus immunoglobulin after the exudative phase of the burn has subsided (about 36 hours after onset of the burn). At the same time, 0.5 ml of tetanus vaccine should be administered in a different extremity with a separate syringe, and the complete immunization schedule should be followed. Therapy of clinically manifest tetanus: For adults and children, single doses of 3,000 to 6,000 IU are given, in combination with other appropriate clinical procedures.